Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

May 15, 2019

SELL
$8.95 - $12.49 $179,000 - $249,800
-20,000 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$10.88 - $14.95 $32,640 - $44,850
3,000 Added 17.65%
20,000 $279,000
Q2 2018

Aug 13, 2018

BUY
$12.24 - $17.05 $176,868 - $246,372
14,450 Added 566.67%
17,000 $208,000
Q1 2018

May 14, 2018

BUY
$15.44 - $17.71 $39,372 - $45,160
2,550 New
2,550 $39,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.14B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Lumina Fund Management LLC Portfolio

Follow Lumina Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lumina Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lumina Fund Management LLC with notifications on news.